(GLOBAL WEBINAR)

SGLT2 Inhibitors and HFpEF:

A PROMISE FULFILLED?

SATURDAY, SEPTEMBER 17TH, 2022

9:00 am CDT / 10:00 am EDT / 3:00 pm BST / 7:30 pm IST

FACULTY



Shelley Zieroth, MD, FRCPC, FCCS, FHFSA, FESC, FACC, FHFA PROGRAM CHAIR

St. Boniface Hospital; Professor of Medicine, University of Manitoba; Winnipeg, MB, Canada



Carolyn S. P. Lam, MBBS, PhD, FRCP, FACC, FAMS, FESC National Heart Centre Singapore; Professor of Medicine, Duke-National University Singapore Medical School; Singapore



John J. V. McMurray,
OBE, BSc (Hons), MB ChB (Hons), MD, FRCP,
FESC, FACC, FAHA, FRSE, FMedSci
Queen Elizabeth University Hospital;
Professor of Medical Cardiology,
University of Glasgow;
Glasgow, Scotland, UK



Scott D. Solomon, MD, FACC, FHFSA Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Boston, MA, USA



Subodh Verma, MD, PhD, FRCSC, FAHA St. Michael's Hospital; Professor of Surgery and Pharmacology & Toxicology, University of Toronto; Toronto, ON, Canada

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists-Association Canadienne des pathologistes. You may claim a maximum of 2.0 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credit to AMA credit can be found at www. ama[1]assn.org/go/internationalcme. Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group.

AGENDA

00:00 - 00:05

Welcome and Opening Remarks

Shelley Zieroth

00:05-00:30

HFpEF: Unraveling the mysteries of a recalcitrant medical problem

Carolyn Lam

00:30-00:55

SGLT2i in the treatment of HFpEF: Have they delivered in clinical trials? Scott Solomon

00:55-01:20

From DAPA-HF to DELIVER:

Does ejection fraction really matter?

John McMurray

01:25-01:45

From Paper to Practice.

Practical tips for physicians

Subodh Verma

01:45-02:05 **Q&A/Panel Discussion**

Learning Objectives

- 1. To outline current and emerging approaches in HFpEF diagnosis
- 2. To describe the latest results from clinical trials studying pharmacotherapies in people with HFpEF
- 3. To explain how to practically personalize HFpEF management with established and novel drugs

To register go to: www.SGLT2iHFpEF.com